EyePoint Pharmaceuticals (EYPT)

Executive Summary

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company leveraging its proprietary Durasert E™ bioerodible delivery platform to develop sustained-release therapies for serious retinal diseases. The lead candidate, DURAVYU™ (EYP-1901), is a long-acting intravitreal injection of vorolanib, a tyrosine kinase inhibitor, currently in pivotal trials for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Positive topline data from the Phase 3 VERONA trial in wet AMD (expected mid-2026) and the Phase 3 LUGANO trial in DME (expected late 2026/early 2027) are key near-term catalysts. Additionally, the company has an approved product, Dexycu, for post-cataract surgery inflammation, providing a commercial foothold. With a strong intellectual property position and a focus on reducing treatment burden for patients, EyePoint represents a promising opportunity in the retinal therapeutics market.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 VERONA topline data for DURAVYU in wet AMD60% success
• Q4 2026Phase 3 LUGANO topline data for DURAVYU in DME55% success
• TBDPotential strategic partnership or licensing deal for DURAVYU ex-US40% success